Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews

Xianglin L. Du, Charles R. Key, Lois Dickie, Ronald Darling, George L. Delclos, Kim Waller, Dong Zhang

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Background: Surveillance, Epidemiology, and End Results (SEER) cancer registries provide accurate information on cancer surgery and radiation, but the validity of registry data on chemotherapy and hormone therapy for breast cancer has not been well studied. We validated the registry data for chemotherapy and hormone therapy against an independent medical chart review. Methods: We identified 1,228 women diagnosed with breast cancer at age >=65 in 1993-1999 in the New Mexico SEER Tumor Registry and completed medical chart reviews. Results: Overall, there was moderate agreement between these two databases on chemotherapy that was received within 6 months of diagnosis. The observed agreement was 96.0%, with a kappa of 0.72 (95% confidence interval: 0.64-0.79). The sensitivity of the registry data for chemotherapy was 70.7% and the specificity was 98.2%. The positive predictive value of the registry data for chemotherapy was 77.8%. The sensitivity of the registry data for hormone therapy was 59.7%, and the specificity was 89.5%. The observed agreement for hormone therapy was 80.0%, with a kappa of 0.52 (0.46-0.57). Conclusion: Agreement on chemotherapy and hormone therapy between the New Mexico SEER Tumor Registry and chart reviews was moderate. The preferred approach would be to combine data from different sources to obtain more complete information.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalJournal of Clinical Epidemiology
Volume59
Issue number1
DOIs
StatePublished - Jan 2006

Keywords

  • Breast cancer
  • Chart review
  • Chemotherapy
  • Hormone therapy
  • SEER
  • Tumor registry

ASJC Scopus subject areas

  • Epidemiology

Fingerprint Dive into the research topics of 'Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews'. Together they form a unique fingerprint.

Cite this